|
|
 |
|
|
|
|
Factoid of the Day
|
Monday, April 14, 2025
|
|
The U.S. Food and Drug Administration (FDA) reported that it approved seven new drugs in Q1'25, according to its own release. The first quarter's tally lags the 10 new drugs approved in Q1'24, as well as the 13 approved in Q1'23. The FDA approved a total of 50 new drugs in 2024, down from 55 approvals in 2023. For comparative purposes, the FDA approved a record 59 novel drugs in 2018.
|
|
First Trust Target Outcome ETFs®
|
| |
Unit Investment Trusts Upcoming Deposit Information |
Initial Offer Date |
| |
Click Here
for CUSIP Information.
|
| • |
Vest Large Cap Buffered 10, 77 |
4/14/2025 |
| • |
Dividend Growers and Tax-Advantaged Income, 43 |
4/15/2025 |
| • |
FT Moderate Buffer ETF Allocation, 3 |
4/15/2025 |
| • |
Inflation Hedge, 61 |
4/15/2025 |
| • |
Select DSIP, 2nd Qtr 2025 |
4/16/2025 |
| • |
Vest Large Cap Deep Buffered 20, 79 |
4/16/2025 |
| • |
Cloud Computing, 49 |
4/17/2025 |
| • |
Cyclical Strength, 50 |
4/17/2025 |
| • |
Sabrient Baker's Dozen, 2nd Qtr 2025 |
4/17/2025 |
| • |
Vest 2-Year Large Cap Buffered 20, 21 |
4/21/2025 |
| • |
Sabrient Small Cap Growth, 46 |
4/22/2025 |
| • |
FT Diversified Target Income, 9 |
4/23/2025 |
| • |
Tactical Income, 85 |
4/23/2025 |
| • |
Vest Enhanced Large Cap Buffered 15, 26 |
4/23/2025 |
| • |
Earnings Leaders, 6 |
4/24/2025 |
| • |
Income Dividend Equity Allocation (IDEA), 45 |
4/24/2025 |
| • |
Mega-Cap, 77 |
4/24/2025 |
| • |
Water Utility & Infrastructure Select, 78 |
4/24/2025 |
| • |
Vest Nasdaq 100 Buffered 10, 17 |
4/25/2025 |
| • |
Equity Income Opportunity, 33 |
4/28/2025 |
| • |
REIT Growth & Income Select, 72 |
4/28/2025 |
| • |
Virtual Economy, 14 |
4/28/2025 |
| • |
Vest Large Cap Buffered 10, 78 |
4/29/2025 |
| • |
Aerospace & Defense, 48 |
4/30/2025 |
| • |
Richard Bernstein Advisors Tactical Series, American Industrial Renaissance®, 2025-2 |
4/30/2025 |
| • |
Balanced Income Equity and ETF, 74 |
5/1/2025 |
| • |
California Municipal Income Closed-End and ETF, 10 |
5/1/2025 |
| • |
Tax Exempt Municipal Income, 340 |
5/1/2025 |
| • |
Content Leaders, 33 |
5/2/2025 |
| • |
Innovative Financial and Technology, 15 |
5/2/2025 |
| • |
International Capital Strength, 67 |
5/2/2025 |
| • |
SMid Capital Strength, 67 |
5/2/2025 |
| • |
Strategic Income Closed-End, 105 |
5/2/2025 |
| • |
Vest Large Cap Deep Buffered 30, 38 |
5/5/2025 |
| • |
Vest Small Cap Buffered 20, 10 |
5/7/2025 |
| • |
SMid Earnings Leaders, 1 |
5/13/2025 |
| • |
Vest Nasdaq 100 Buffered 20, 22 |
5/13/2025 |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|